5. New Opioid Prescribing Guidance Targets Inpatient Acute Pain Management

Until now, there has been little guidance on the safe prescribing of opioids in the inpatient, non-operative setting. Read more.

4. FDA Approves First-Line Treatment Combo for Advanced Renal Cell Carcinoma

Opdivo and Yervoy combination is the first and only treatment to show significantly superior survival compared with sunitinib in intermediate- and poor-risk advanced RCC. Read more.

3. Inlyta Fails to Demonstrate Efficacy in Patients at High Risk of Recurrent Renal Cell Carcinoma

In its phase 3 trial, Pfizer’s axitinib (Inlyta) did not achieve disease-free survival in patients at high risk of recurrent renal cell carcinoma after nephrectomy. Read more.

2. Merck Announces Positive Phase 3 Results for Keytruda as Lung Cancer Therapy

Pembrolizumab (Keytruda) met its primary endpoint in the pivotal phase 3 KEYNOTE-042 trial. Read more.

1. FDA Approves Osimertinib for Treatment of Non-Small Cell Lung Cancer

Osimertinib surpassed standard of care with a median progression-free survival of 18.9 months in clinical trials. Read more.